Seres Therapeutics initiates enrollment in Cohort 2 in SER-155 trial

Seres Therapeutics announced that enrollment in Cohort 2 in its SER-155 Phase 1b study is underway. SER-155, an investigational oral microbiome therapeutic, is designed to reduce the incidence of gastrointestinal, or GI, infections, bloodstream infections, and graft versus host disease, or GvHD, in individuals undergoing allogeneic hematopoietic stem cell transplantation, or allo-HSCT.